Quarterly report pursuant to Section 13 or 15(d)

LICENSE AGREEMENTS - Additional Information - (Detail)

v3.21.1
LICENSE AGREEMENTS - Additional Information - (Detail) - USD ($)
$ in Thousands
 1 Months Ended 9 Months Ended
Dec. 03, 2020
Oct. 23, 2020
Oct. 09, 2020
Aug. 04, 2017
Oct. 31, 2020
Mar. 31, 2020
Mar. 31, 2021
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Proceeds from private placement of equity shares     $ 41,000        
Stock Issued During Period, Value, Issued for Services             $ 7
License agreement              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Stock Issued During Period, Value, Issued for Services           $ 2,600  
Activesite Pharmaceuticals Inc              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Milestone Payments $ 1,000            
Maximum Amount of Milestone Events       $ 46,500      
First milestone payment due after completion of the preclinical work       $ 1,000      
Royalties percentage       2.00%      
Xoma              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Milestone Payments             $ 37,000
Proceeds from private placement of equity shares         $ 41,000    
Payments of outstanding balance of license   $ 1,400          
Xoma | License agreement              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Stock Issued During Period, Shares, Other             162,000
Put Option [Member] | Xoma | License agreement              
Research and Development Arrangement, Contract to Perform for Others [Line Items]              
Description Of Option Indexed To Issuers Equity Shares             Xoma was permitted to exercise the Put Option for up to a total of 50,000 shares of Common Stock for the calendar year ending December 31, 2020, and up to an additional 50,000 shares thereafter.